Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens
Open Access
- 29 July 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (15) , 4867-4874
Abstract
Purpose: The development of effective therapeutic approaches for treatment of metastatic melanoma remains an immense challenge. Present therapies offer minimal benefit. Although dacarbazine chemotherapy remains the standard therapy, it mediates only low response rates, usually of short duration, even when combined with other chemotherapeutic agents. Thus, new therapeutic strategies are urgently needed. Experimental Design: Using a newly developed preclinical model, we evaluated the efficacy of various doublet metronomic combination chemotherapy against established advanced melanoma metastasis and compared these with the standard maximum tolerated dose dacarbazine (alone or in combination with chemotherapeutic agents or vascular endothelial growth factor receptor–blocking antibody). Results: Whereas maximum tolerated dose dacarbazine therapy did not cause significant improvement in median survival, a doublet combination of low-dose metronomic vinblastine and low-dose metronomic cyclophosphamide induced a significant increase in survival with only minimal toxicity. Furthermore, we show that the incorporation of the low-dose metronomic vinblastine/low-dose metronomic cyclophosphamide combination with a low-dose metronomic dacarbazine regimen also results in a significant increase in survival, but not when combined with maximum tolerated dose dacarbazine therapy. We also show that a combination of metronomic vinblastine therapy and a vascular endothelial growth factor receptor 2–blocking antibody (DC101) results in significant control of metastatic disease and that the combination of low-dose metronomic vinblastine/DC101 and low-dose metronomic dacarbazine induced a significant improvement in median survival. Conclusions: The effective control of advanced metastatic melanoma achieved by these metronomic-based chemotherapeutic approaches warrants clinical consideration of this treatment concept, given the recent results of a number of metronomic-based chemotherapy clinical trials.Keywords
This publication has 33 references indexed in Scilit:
- Adjuvant therapy of melanoma with interferon: lessons of the past decadeJournal of Translational Medicine, 2008
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast CancerJournal of Clinical Oncology, 2008
- On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testingCancer and Metastasis Reviews, 2007
- Tumor‐targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low‐dose metronomic regimens in a murine melanoma modelInternational Journal of Cancer, 2007
- Temozolomide for the Treatment of Metastatic MelanomaCurrent Oncology, 2007
- MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma researchBreast Cancer Research and Treatment, 2006
- Common origins of MDA-MB-435 cells from various sources with those shown to have melonoma propertiesClinical & Experimental Metastasis, 2004
- Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far‐advanced melanoma and soft tissue sarcomaCancer, 2004
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Orthotopic models of cancer for preclinical drug evaluationEuropean Journal of Cancer, 2004